133 related articles for article (PubMed ID: 12956760)
1. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
2. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
4. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
Hofmann UB; Voigt H; Andersen MH; Straten PT; Becker JC; Eggert AO
Eur J Immunol; 2009 May; 39(5):1419-24. PubMed ID: 19337999
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
7. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
8. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
Ciesielski MJ; Apfel L; Barone TA; Castro CA; Weiss TC; Fenstermaker RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1491-503. PubMed ID: 16485128
[TBL] [Abstract][Full Text] [Related]
10. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
12. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
14. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
[TBL] [Abstract][Full Text] [Related]
16. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.
Schmitz M; Diestelkoetter P; Weigle B; Schmachtenberg F; Stevanovic S; Ockert D; Rammensee HG; Rieber EP
Cancer Res; 2000 Sep; 60(17):4845-9. PubMed ID: 10987296
[TBL] [Abstract][Full Text] [Related]
17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
19. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency.
Yang Z; Wang L; Wang H; Shang X; Niu W; Li J; Wu Y
Mol Immunol; 2008 Mar; 45(6):1674-81. PubMed ID: 18035418
[TBL] [Abstract][Full Text] [Related]
20. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
